Good day, and thank you for standing by. Welcome to ALS Limited H1 FY '26 results briefing. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ALS Ltd. announces a change in ...

Earnings call ALS Limited delivered strong H1 FY26 results with revenue up 13.3% YoY to AUD 1.7 billion and underlying EBIT up 14.7% to AUD 287.2 million, driven by broad-based organic growth and ...

In a report released today, Nathan Reilly from UBS maintained a Hold rating on ALS Ltd. (CPBLF – Research Report), with a price target of A$13.30. The company’s shares closed last Wednesday at $8.51.

ALS Ltd. has reported its financial results for the first half of fiscal year 2025, highlighting changes in its investment in Nuvisan, moving from a 49% to a 100% consolidated stake. The company’s ...

We increase our fair value estimate for no-moat-rated ALS by 2.5% to AUD 8.60, driven largely by the time value of money. The materials testing specialist also reported stronger-than-expected ...

Australia’s ALS Ltd. is seeking to raise up to A$390 million ($253 million) as the testing services company looks to expand its laboratory network. ALS plans to raise the capital through a fully ...

We upgrade ALS Limited’s moat rating to narrow from no moat, and accordingly, our fair value estimate rises by 12% to AUD 10.20 per share. We estimate returns on invested capital, including goodwill, ...

ALS Ltd. engages in the provision of analytical and testing services businesses and partnerships. It operates through the following segments: Life Sciences, Commodities, Industrial, and Other. The ...

Please be advised that today's conference is being recorded. I would now like to turn the call over to your first speaker today, Mr. Malcolm Deane, CEO and Managing Director. Thank you. Please go ...

Earnings call ALS delivered record FY26 results, exceeding FY27 targets a year early with revenue up 10.7% to AUD 3.32bn and underlying NPAT up 25.8% to AUD 381.2m. Management guides for continued mid ...